Top Markets
Coin of the day
Galmed Pharmaceuticals Ltd. Galmed Pharmaceuticals Ltd.

Galmed Pharmaceuticals Ltd.

GLMD
株式のランク #35178
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the... Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company develops MyBiotics which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.
株価
$0.5225
最終同期: 2026-08-14
時価総額
$4.32M
変化(1日)
-1.60%
変化(1年)
-63.72%
IL
取引 Galmed Pharmaceuticals Ltd. (GLMD)

カテゴリー

Galmed Pharmaceuticals Ltd.(GLMD)の株価履歴
終値の最高値: $0.57 (2026-08-01)

終値の最安値: $2.34K (2014-03-01)
Galmed Pharmaceuticals Ltd. の株価履歴(2014 ~ 2026)
年間株価パフォーマンス
パフォーマンス
2026 (TTM) -9.47%
2025 -67.60%
2024 -35.91%
2023 -93.04%
2022 -82.49%
2021 -40.56%
2020 -40.27%
2019 -24.43%
2018 -7.34%
2017 144.28%
2016 -57.96%
2015 53.42%
2014 0.00%
類似企業または競合の株価
企業 株価 変化率 1年%
$505.24 28.63%
US
$846.09 29.41%
NL
$731.69 6.47%
CH
$1.07K -6.40%
KR
$251.82 11.75%
BE